Cargando…

Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities

Multiple genetic and environmental factors are likely to contribute to the development of Alzheimer's disease (AD). The most important known risk factor for AD is presence of the E4 isoform of apolipoprotein E (apoE). Epidemiological studies demonstrated that apoE4 carriers have a higher risk a...

Descripción completa

Detalles Bibliográficos
Autor principal: Cedazo-Mínguez, Angel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4401287/
https://www.ncbi.nlm.nih.gov/pubmed/18205697
http://dx.doi.org/10.1111/j.1582-4934.2007.00130.x
_version_ 1782367124209008640
author Cedazo-Mínguez, Angel
author_facet Cedazo-Mínguez, Angel
author_sort Cedazo-Mínguez, Angel
collection PubMed
description Multiple genetic and environmental factors are likely to contribute to the development of Alzheimer's disease (AD). The most important known risk factor for AD is presence of the E4 isoform of apolipoprotein E (apoE). Epidemiological studies demonstrated that apoE4 carriers have a higher risk and develop the disease and an early onset. Moreover, apoE4 is the only molecule that has been associated with all the biochemical disturbances characteristic of the disease: amyloid-beta (Aβ) deposition, tangle formation, oxidative stress, lipid homeostasis deregulation, synaptic plasticity loss and cholinergic dysfunction. This large body of evidence suggest that apoE is a key player in the pathogenesis of AD. This short review examines the current facts and hypotheses of the association between apoE4 and AD, as well as the therapeutic possibilities that apoE might offer for the treatment of this disease.
format Online
Article
Text
id pubmed-4401287
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-44012872015-04-27 Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities Cedazo-Mínguez, Angel J Cell Mol Med Reviews Multiple genetic and environmental factors are likely to contribute to the development of Alzheimer's disease (AD). The most important known risk factor for AD is presence of the E4 isoform of apolipoprotein E (apoE). Epidemiological studies demonstrated that apoE4 carriers have a higher risk and develop the disease and an early onset. Moreover, apoE4 is the only molecule that has been associated with all the biochemical disturbances characteristic of the disease: amyloid-beta (Aβ) deposition, tangle formation, oxidative stress, lipid homeostasis deregulation, synaptic plasticity loss and cholinergic dysfunction. This large body of evidence suggest that apoE is a key player in the pathogenesis of AD. This short review examines the current facts and hypotheses of the association between apoE4 and AD, as well as the therapeutic possibilities that apoE might offer for the treatment of this disease. Blackwell Publishing Ltd 2007-11 2007-10-22 /pmc/articles/PMC4401287/ /pubmed/18205697 http://dx.doi.org/10.1111/j.1582-4934.2007.00130.x Text en
spellingShingle Reviews
Cedazo-Mínguez, Angel
Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities
title Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities
title_full Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities
title_fullStr Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities
title_full_unstemmed Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities
title_short Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities
title_sort apolipoprotein e and alzheimer's disease: molecular mechanisms and therapeutic opportunities
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4401287/
https://www.ncbi.nlm.nih.gov/pubmed/18205697
http://dx.doi.org/10.1111/j.1582-4934.2007.00130.x
work_keys_str_mv AT cedazominguezangel apolipoproteineandalzheimersdiseasemolecularmechanismsandtherapeuticopportunities